DEFRA ‘Call for Information’: UK–EU SPS Agreement – Impact on UK Medical Cannabis Cultivation
The CIC has responded to DEFRA’s “Call for Information” on a proposed UK–EU Sanitary and Phytosanitary (SPS) Agreement. We are concerned that the SPS Agreement risks undermining the UK’s domestic cultivation sector at a critical stage of its development, especially if no exemptions can be negotiated with the EU.
The SPS Agreement presents both opportunities and risks. Its implementation must support, and not weaken, the development of a robust, high-quality UK medical cannabis industry.
We therefore recommend that DEFRA:
- Ensures a level playing field between domestic and imported products
- Maintains appropriate UK regulatory oversight and flexibility
- Recognises and supports the role of domestic cultivation in supply resilience
- Develops a clear strategic framework for the activities within the broader medical cannabis sector for which it has oversight
The Cannabis Industry Council and its members are more than willing to work collaboratively with DEFRA and other regulators to support effective policy design and implementation.
We would welcome the opportunity to:
- Share industry data and operational insight
- Support the development of proportionate, workable regulation
- Contribute to solutions that balance trade facilitation with domestic growth
- Help design a sustainable, patient-focused supply model for the UK
Our shared objective is clear: to ensure that UK patients have access to consistent, high-quality medical cannabis, supported by a resilient and well-regulated supply chain. This Call for Information will be closing on 23 April 2026.
Members interested in reading the CIC’s response to DEFRA can contact enquiries@cicouncil.org.uk.
